Bulletin of Experimental Biology and Medicine

, Volume 162, Issue 4, pp 421–424 | Cite as

Cystatin C as a Marker of Progressing Cardiovascular Events during Coronary Heart Disease

  • M. M. Gevorgyan
  • N. P. Voronina
  • N. V. Goncharova
  • T. V. Kozaruk
  • G. S. Russkikh
  • L. A. Bogdanova
  • T. A. Korolenko
GENERAL PATHOLOGY AND PATHOPHYSIOLOGY
  • 73 Downloads

The role of cystatin C, an inhibitor of cysteine proteases, as an alternative and potent predictor of acute cardiovascular events in coronary heart disease (CHD) patients was examined and compared to that of other markers of cardiorenal abnormalities. The patients with CHD demonstrated elevated serum cystatin C, especially in cases with serious risk of cardiovascular complications. In comparison with other indicators of cardiorenal dysfunction, cystatin C can be viewed as an alternative predictor of cardiovascular complications, although its sensitivity is inferior to that of high-sensitivity C-reactive protein and natriuretic peptide.

Key Words

cystatin C coronary heart disease biochemical markers clinical study 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cherkanova MS, Korolenko TA, Yu Brawe I, Gerasimova TP. Effect of statins on activity of matrix metalloproteases and serum concentration of cystatin C in patients with various risk of development of ischemic heart disease and in patients after coronary artery bypass surgery. Kardiologiya. 2012;52(2):23-28. Russian.Google Scholar
  2. 2.
    Bengtsson E, Nilsson J, Jovinge S. Cystatin C and cathepsins in cardiovascular disease. Front Biosci. 2008;13:5780-5786.CrossRefPubMedGoogle Scholar
  3. 3.
    Frendéus KH, Wallin H, Janciauskiene S, Abrahamson M. Macrophage responses to interferon-gamma are dependent on cystatin C levels. Int. J. Biochem. Cell Biol. 2009;41(11):2262-2269.CrossRefPubMedGoogle Scholar
  4. 4.
    Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I; IFCC Working Group on Standardisation of Cystatin C (WG-SCC). First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin. Chem. Lab. Med. 2010;48(11):1619-1621.Google Scholar
  5. 5.
    Korolenko TA, Cherkanova MS, Gashenko EA, Johnston TP, Bravve IY. Cystatin C, atherosclerosis and lipid-lowering therapy by statins. Cystatins: Protease Inhibitors, Biomarkers and Immunomodulators. Cohen JB, Rysek LP, eds. New York, 2011. P. 187-204.Google Scholar
  6. 6.
    Korolenko T, Cherkanova M, Gerasimova T, Korolenko Ts. Matrix metalloproteases, chitotriosidase and cystatin C in long-term study in patients after cardiosurgery. New Insights into Mechanisms and Management of Heart Disease. Kimchi A, ed. Vancouver, 2014. P. 57-86.Google Scholar
  7. 7.
    Korolenko TA, Rukavishnikova EV, Safina AF, Dushkin MI, Mynkina GI. Endocytosis by liver cells during suppression of intralysosomal proteolysis. Biol. Chem. Hoppe Seyler. 1992;373(7):573-580.CrossRefPubMedGoogle Scholar
  8. 8.
    Korolenko TA, Svechnikova IG, Filjushina EE, Kaledin VI, Vakulin GM, Usynin IF, Tsyrendordjiev DD. Macrophage stimulation and antitumor effect of Ukrain. Drugs Exp. Clin. Res. 1998;24(5-6):253-260.PubMedGoogle Scholar
  9. 9.
    Lv BJ, Lindholt JS, Cheng X, Wang J, Shi GP. Plasma cathepsin S and cystatin C levels and risk of abdominal aortic aneurysm: a randomized population-based study. PLoS One. 2012;7(7):e41813.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Nagesh CM, Roy A. Role of biomarkers in risk stratification of acute coronary syndrome. Indian J. Med. Res. 2010;132:627-633.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Safina AF, Korolenko TA, Mynkina GI, Dushkin MI, Krasnoselskaya GA. Liver and serum lysosomal enzymes activity during zymosan-induced inflammation in mice. Agents Actions Suppl. 1992;38(Pt 3):370-375.PubMedGoogle Scholar
  12. 12.
    Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J. Am. Soc. Nephrol. 2006;17(1):254-261.CrossRefPubMedGoogle Scholar
  13. 13.
    Wallin H, Abrahamson M, Ekström U. Cystatin C properties rucial for uptake and inhibition of intracellular target enzymes. J. Biol. Chem. 2013;288(23):17,019-17,029.CrossRefGoogle Scholar
  14. 14.
    Zhao C, Yang L, Mao L, Zhong L, Li X, Wei S. Cystatin C associates with the prediction of in-stent restenosis among patients receiving stent implantation: results of the 1-year followup. Coron. Artery Dis. 2013;24(5):357-360.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhu Y, Zhang HP, Wang YC, Ren TT, Li J, Xu ML, Wang XQ, Liu F.C, Lau A, Wen YF. Serum cystatin C level is associated with carotid intima-media thickening and plaque. Scand. J. Clin. Lab. Invest. 2015;75(3):265-272.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • M. M. Gevorgyan
    • 1
  • N. P. Voronina
    • 2
  • N. V. Goncharova
    • 1
  • T. V. Kozaruk
    • 2
  • G. S. Russkikh
    • 1
  • L. A. Bogdanova
    • 3
  • T. A. Korolenko
    • 1
  1. 1.Research Institute of Physiology and Fundamental MedicineNovosibirskRussia
  2. 2.Research Institute of BiochemistryNovosibirskRussia
  3. 3.Research Institute of Molecular Pathology and PathomorphologyNovosibirskRussia

Personalised recommendations